AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)

This study is currently recruiting participants.
Verified December 2011 by University Hospital Freiburg
Sponsor:
Collaborator:
Wako Diagnostics
Information provided by (Responsible Party):
Dominik Bettinger, University Hospital Freiburg
ClinicalTrials.gov Identifier:
NCT01360255
First received: May 9, 2011
Last updated: December 14, 2011
Last verified: December 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2011
  Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)